Unveiling the Dual Benefits of Bosentan in Systemic Sclerosis: Risk and Relief
Open Access
- 15 February 2025
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (4) , 305-307
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Myocardial Disease in Systemic Sclerosis: Recent Updates and Clinical ImplicationsCurrent Cardiology Reports, 2025
- Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic SclerosisCurrent Rheumatology Reports, 2019
- Digital ulcers predict a worse disease course in patients with systemic sclerosisAnnals of the Rheumatic Diseases, 2016
- Management of Raynaud Phenomenon and Digital Ulcers in SclerodermaRheumatic Disease Clinics of North America, 2015
- Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT studyAnnals of the Rheumatic Diseases, 2014
- Meta‐Analysis of Healing and Prevention of Digital Ulcers in Systemic SclerosisArthritis Care & Research, 2013
- Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long‐term survivalArthritis & Rheumatism, 2011
- Associations with digital ulcers in a large cohort of systemic sclerosis: Results from the Canadian Scleroderma Research Group registryArthritis Care & Research, 2010
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Expression of Endothelin-1 in the Lungs of Patients with Pulmonary HypertensionNew England Journal of Medicine, 1993